Analyst: one foot in the Promised Land
Last week’s recommendation of Tresiba from an FDA advisory panel puts Novo Nordisk in a strong position. Read on to see what one analyst feels will be the deciding factors for Novo's market position in the US.
by Stefan Singh Kailay
“Novo Nordisk is in a very, very strong position. Of course the FDA is not obligated to follow this recommendation from the advisory panel, but historically speaking there has always been a great coherence between the final decision and the recommendation from the panel. Novo Nordisk has taken a great step towards marketing Tresiba in the US.”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
